455 Mission Bay Boulevard South
San Francisco, CA 94158
United States
415 482 5300
https://www.nektar.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 137
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Howard W. Robin | CEO, President & Director | 1.83M | N/A | 1953 |
Mr. Mark A. Wilson | Senior VP, Chief Legal Officer & Secretary | 749.99k | N/A | 1972 |
Dr. Jonathan Zalevsky Ph.D. | Chief Research & Development Officer | 1.25M | N/A | 1975 |
Ms. Sandra A. Gardiner | Interim Chief Financial Officer | N/A | N/A | 1966 |
Vivian Wu | Director of Investor Relations & Corporate Affairs | N/A | N/A | N/A |
Mr. Robert Bacci | Senior Vice President of Human Resources & Facilities Operations | N/A | N/A | N/A |
Ms. Jennifer Ruddock | Chief Business Officer | N/A | N/A | N/A |
Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer | N/A | N/A | 1966 |
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Nektar Therapeutics’s ISS Governance QualityScore as of March 1, 2024 is 6. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 2; Compensation: 8.